Marshall IslandsTuberculosis profile
Population  2014 <1 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.02 (0.014–0.028) 38 (26–53)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 0.25 (0.12–0.43) 466 (218–806)
Incidence  (includes HIV+TB) 0.18 (0.14–0.21) 335 (274–402)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.68 (0.5–0.88)
         
Case detection, all forms (%) 80 (67–98)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 0 (0–8) 0 (0–41)
MDR-TB cases among notified pulmonary
TB cases
0 (0–8) 0 (0–7)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 53   4
Pulmonary, clinically diagnosed 46   1
Extrapulmonary 37   1
       
Total new and relapse 142    
Previously treated, excluding relapses 11    
Total cases notified 153    
Among 57 new and relapse cases:
2 (4%) cases aged under 15 years; male:female ratio: 0.8
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 82 (155%) 7 (41%) 89
Laboratory-confirmed RR-/MDR-TB cases     0
Patients started on MDR-TB treatment ***     0
TB/HIV 2014 Number (%)
TB patients with known HIV status 95 (62)
HIV-positive TB patients 0 (0)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0  
HIV-positive TB patients on antiretroviral therapy (ART) 0  
HIV-positive people screened for TB 0  
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (89) 153
Previously treated cases, excluding relapse, registered in 2013   1
HIV-positive TB cases, all types, registered in 2013   1
RR-/MDR-TB cases started on second-line treatment in 2012 (75) 4
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 3.8
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 2
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-06-28 Data: www.who.int/tb/data